Bishal Gyawali, Associate Professor at Queen’s University, shared a post on LinkedIn:
“Subcutaneous immunotherapy- patient convenience or patent hopping? Our paper was one of the most-talked Journal of Clinical Oncology articles last week.”
Title: Beyond Convenience: Does Subcutaneous Pembrolizumab Add Value for Patients and Health Systems?
Authors: Laure-Anne Teuwen, Rachel P. Riechelmann, Bishal Gyawali
Read the Full Article.
Other articles featuring Bishal Gyawali on OncoDaily.
